Prophylaxis in hereditary angioedema: a United Kingdom Delphi consensus

被引:0
作者
Yong, Patrick F. K. [1 ]
Annals, Rachel [2 ]
Diwakar, Lavanya [3 ]
Elkhalifa, Shuayb [4 ]
Gompels, Mark [5 ]
Jain, Rashmi [6 ]
Karim, Mohammed Yousuf [7 ]
Khan, Sujoy [8 ]
Metcalfe, Angela [2 ]
Noorani, Sadia [9 ]
Steele, Cathal [10 ]
Kiani-Alikhan, Sorena [11 ]
Garcez, Tomaz [12 ]
机构
[1] Frimley Hlth NHS Fdn Trust, Dept Immunol, Frimley, England
[2] Hereditary Angioedema UK, Bridgwater, England
[3] Univ Hosp North Midlands NHS Trust, Dept Immunol, Stoke On Trent, England
[4] Cleveland Clin Abu Dhabi, Dept Allergy & Immunol, Abu Dhabi, U Arab Emirates
[5] North Bristol NHS Trust, Dept Immunol, Bristol, England
[6] Oxford Univ Hosp NHS Fdn Trust, Dept Clin Immunol, Oxford, England
[7] Sidra Med, Hematopatho, Doha, Qatar
[8] Hull Univ Teaching Hosp NHS Trust, Dept Immunol & Allergy, Kingston Upon Hull, England
[9] Sandwell & West Birmingham NHS Trust, Dept Immunol, Birmingham, England
[10] Royal Hosp Belfast, Reg Immunol Serv, Belfast, North Ireland
[11] Royal Free London NHS Fdn Trust, Dept Immunol, London, England
[12] Manchester Univ NHS Fdn Trust, Dept Immunol, Manchester, England
关键词
hereditary angioedema; HAE; C1 inhibitor deficiency; prophylaxis; Delphi consensus; C1 INHIBITOR DEFICIENCY;
D O I
10.1093/cei/uxae020
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Hereditary angioedema (HAE) is a rare inherited disorder causing recurrent episodes of swelling that can be potentially life threatening. Treatment of HAE can be divided into on-demand treatment for swelling, and prophylaxis. The last UK consensus on HAE was in 2014 and since then, new medications for prophylaxis have been developed, with more drugs in the pipeline. International guidelines currently recommend the use of long-term prophylaxis (LTP) as the only way of achieving disease control and normalizing patient lives. Modern prophylactic medications are available in the UK, although access is restricted primarily by HAE attack frequency. To establish an updated view of UK clinicians and patients, a Delphi process was used to develop statements regarding LTP as well as other aspects of HAE management. There was consensus that UK access criteria for modern LTP agents based on numerical frequency of attacks alone are too simplistic and potentially disadvantage a cohort of patients who may benefit from LTP. Additionally, there was agreement that patients should be seen in expert centres, remote monitoring of patients is popular post-pandemic, and that the use of patient-reported outcome measures has the potential to improve patient care. Psychological health is an area in which patients may benefit, and recognition of this is important for future research and development. To establish an updated view of UK clinicians and patients, a Delphi process was used to develop statements regarding long-term prophylaxis and other aspects of hereditary angioedema management. UK access criteria for modern LTP agents based on numerical frequency of attacks alone were thought to be too simplistic, and potentially disadvantage a cohort of patients who may benefit from LTP. There was agreement that patients should be seen in expert centres, remote monitoring of patients is popular post-pandemic, patient-reported outcome measures has the potential to improve patient care, and psychological support may benefit patients.
引用
收藏
页码:109 / 116
页数:8
相关论文
共 11 条
[1]  
[Anonymous], 2016, Clinical commissioning policy statement: Docetaxel in combination with androgen deprivation therapy for the treatment of hormone naive metastatic prostate cancer
[2]   Comorbidities in hereditary angioedema-A population-based cohort study [J].
Bjorkman, Linda Sundler ;
Persson, Barbro ;
Aronsson, David ;
Skattum, Lillemor ;
Nordenfelt, Patrik ;
Egesten, Arne .
CLINICAL AND TRANSLATIONAL ALLERGY, 2022, 12 (03)
[3]   Patient-reported Outcome Measures for Angioedema: A Literature Review [J].
Brix, Anna Trier Heiberg ;
Boysen, Henrik Balle ;
Weller, Karsten ;
Caballero, Teresa ;
Bygum, Anette .
ACTA DERMATO-VENEREOLOGICA, 2021, 101
[4]   Hereditary Angioedema [J].
Busse, Paula J. ;
Christiansen, Sandra C. .
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (12) :1136-1148
[5]   C1 inhibitor deficiency: 2014 United Kingdom consensus document [J].
Longhurst, H. J. ;
Tarzi, M. D. ;
Ashworth, F. ;
Bethune, C. ;
Cale, C. ;
Dempster, J. ;
Gompels, M. ;
Jolles, S. ;
Seneviratne, S. ;
Symons, C. ;
Price, A. ;
Edgar, D. .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2015, 180 (03) :475-483
[6]   The international WAO/EAACI guideline for the management of hereditary angioedema-The 2021 revision and update [J].
Maurer, Marcus ;
Magerl, Markus ;
Betschel, Stephen ;
Aberer, Werner ;
Ansotegui, Ignacio J. ;
Aygoeren-Puersuen, Emel ;
Banerji, Aleena ;
Bara, Noemi-Anna ;
Boccon-Gibod, Isabelle ;
Bork, Konrad ;
Bouillet, Laurence ;
Boysen, Henrik Balle ;
Brodszki, Nicholas ;
Busse, Paula J. ;
Bygum, Anette ;
Caballero, Teresa ;
Cancian, Mauro ;
Castaldo, Anthony ;
Cohn, Danny M. ;
Csuka, Dorrottya ;
Farkas, Henriette ;
Gompels, Mark ;
Gower, Richard ;
Grumach, Anete S. ;
Guidos-Fogelbach, Guillermo ;
Hide, Michihiro ;
Kang, Hye-Ryun ;
Kaplan, Allen Phillip ;
Katelaris, Constance ;
Kiani-Alikhan, Sorena ;
Lei, Wei-Te ;
Lockey, Richard ;
Longhurst, Hilary ;
Lumry, William R. ;
MacGinnitie, Andrew ;
Malbran, Alejandro ;
Saguer, Inmaculada Martinez ;
Matta, Juan Jose ;
Nast, Alexander ;
Nguyen, Dinh ;
Nieto-Martinez, Sandra A. ;
Pawankar, Ruby ;
Peter, Jonathan ;
Porebski, Grzegorz ;
Prior, Nieves ;
Reshef, Avner ;
Riedl, Marc ;
Ritchie, Bruce ;
Sheikh, Farrukh Rafique ;
Smith, William R. .
ALLERGY, 2022, 77 (07) :1961-1990
[7]  
NICE, 2019, LANADELUMAB PREVENTI
[8]  
NICE, 2021, BEROTRALSTAT PREVENT
[9]  
qpids, ROYAL COLL PHYS QUAL
[10]  
Royal College of Physicians, WORKING DIFFERENTLY